Published July 13, 2026
Latest Drug Approvals from Health Canada
Weekly roundup of notable drug approvals relevant to Canada's pharmacies.
Read more about Latest Drug Approvals from Health CanadaPublished July 2, 2026
The Economic Footprint of Canada's Pharmacy Sector
Commissioned by the Neighbourhood Pharmacy Association of Canada and independently prepared by Signal49 Research, The Economic Footprint of Canada's Pharmacy Sector: Fuelling Health and Local Economi…
Read more about The Economic Footprint of Canada's Pharmacy SectorPublished April 21, 2026
Drug Pipeline Insights: Biosimilars
Our 2026 Q1 Biosimilars Insights shows an increasingly crowded biosimilars market—led by blockbuster biologics like aflibercept and denosumab—creates new competitive dynamics and savings opportunitie…
Read more about Drug Pipeline Insights: BiosimilarsPublished April 21, 2026
Drug Pipeline Insights: New Drugs
Our 2026 Q1 New Drugs Insights demonstrates how the the latest round of new drug approvals and submissions, from rare disease breakthroughs to cutting-edge oncology therapies, is set to res…
Read more about Drug Pipeline Insights: New DrugsPublished April 21, 2026
Drug Pipeline Insights: Generic Pharmaceuticals
Our 2026 Q1 Generics Insights highlights a wave of high-value generic launches—including major diabetes and oncology drugs—signaling one of the most commercially impactful years for pharmacy in over …
Read more about Drug Pipeline Insights: Generic PharmaceuticalsPublished April 21, 2026
Drug Pipeline Spotlight: Semaglutide
Our Drug Pipeline Spotlight on Semaglutide explores the explosive growth of GLP-1 therapies like Ozempic, Wegovy, and Rybelsus, the anticipated entry of generics in 2026, and what it all means for ph…
Read more about Drug Pipeline Spotlight: Semaglutide